You are here

Share:

Search Technologies

Showing 61-80 of 337 results found

Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2

Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.

Cell Lines Expressing Nuclear and/or Mitochondrial RNAse H1

The National Institute of Child Health & Human Development (NICHD), Program in Genomics of Differentiation, seeks interested parties to further co-develop small molecule inhibitors of RNase H1, especially in regards to genome instability, transcription, and translation.

Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy

There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have designed novel chimeric adaptor proteins (CAPs) consisting of signaling molecules downstream of the T cell receptor (TCR) for use in T cell-mediated immunotherapy. NCI is seeking parties interested in licensing and/or co-developing CAPs that can be used in immunotherapy for treating cancer, including both hematological and solid malignancies.

Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy

Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.

Chimeric Antigen Receptors to CD276 for Treating Cancer

This licensing opportunity from the National Cancer Institute concerns the development of CARs comprising an antigen-binding fragment derived from the MGA271 antibody. The resulting CARs can be used in adoptive cell therapy treatment for neuroblastoma and other tumors that express CD276.

Clinical Imaging with Acoustic Wave or Photoacoustic Tomosynthesis

Ultrasound-based cancer screening and biopsy imaging technique are a critical clinical need. Ultrasound based biopsy imaging can provide a real-time modality for lower cost that is comparable to, or complimentary to MRI imaging. Researchers at the NIH Clinical Center seek licensing and/or co-development research collaborations for Tissue Characterization with Acoustic Wave Tomosynthesis.

Clinical Outcome Predictors for Mantle Cell Lymphoma

The invention is a novel methodology for predicting a mantle cell lymphoma (MCL) cancer patient’s survival prognosis. This information is important in helping determine the best course of treatment for the patient.

Coacervate Micoparticles Useful for the Sustained Release of Therapeutic Agents

Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process; the biodegradable microbead or microparticle is useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest. The microparticles have a matrix structure comprised of the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component (e.g. gelatin, chondroitin sulfate, avidin).

Combination Cancer Therapy with HDAC Inhibitors

NCI researchers developed a combination therapy of histone deacetylase (HDAC) inhibitors and immunotherapies, such as checkpoint inhibitors, virus-based vaccines, monoclonal antibodies, cell-based treatments or radiopharmaceuticals. The NCI Laboratory of Tumor Immunology and Biology seeks parties to license or co-develop this method.

Combination Therapy for Prostate and Breast Cancer

Researchers at the National Cancer Institute developed a novel method of immunogenic modulation in androgen and endocrine deprivation therapy. A combination of hormone therapy with immunotherapies such as PROSTVAC™, a Brachyury vaccine, PROVENGE™, ipilumimab, nivolumab, XOFIGO™, PANVAC, a yeast-MUC-1 immunotherapeutic, or HERCEPTIN™ can benefit prostate and breast cancer patients, especially those who have acquired resistances. The researchers seek parties to co-develop this method.

Compounds that Interfere with the Androgen Receptor Complex

NCI researchers have identified novel compounds that inhibit FKBP52-mediated activation of the androgen receptor protein (AR), a major target for anti-prostate cancer therapeutic development. As FKBP52 is implicated in the regulation of other hormone receptors, anti-FKBP52 may be applicable in the treatment of hormone-dependent diseases such as diabetes or even used as contraceptives. NCI seeks partners to license or co-develop this technology.

Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer

Researchers at the National Institutes for Health Clinical Center (NIHCC) have developed computer-aided diagnostics (CAD) that may further improve the already superior capabilities of multiparametric magnetic resonance imaging (MRI) for detection and imaging of prostate cancer. This system produces an accurate probability map of potential cancerous lesions in multiparametric MRI images that is superior to other systems and may have multiple product applications.

Conserved Elements Vaccine for HIV

Researchers at the National Cancer Institute (NCI) developed a DNA vaccine using conserved elements of HIV-1 Gag, administered in a prime-boost vaccination protocol. Two of the HIV Gag CE DNA vectors have been tested in a rhesus macaque model. Priming with the Gag CE vaccine and boosting with full length Gag DNA showed increased immune responses when compared to vaccination with Gag alone. Researchers seek licensing and/or co-development research collaborations for development this DNA vaccine.

Convolutional Neural Networks for Organ Segmentation

Computer automated segmentation of high variability organs and disease features in medical images is uniquely difficult. The application of deep learning and specialized neural networks may allow for automation of such interpretation tasks that are currently only performed by trained physicians. Computer automation may improve image analysis capabilities and lead to better diagnostics, disease monitoring, and surgical planning for many diseases. To help solve this challenge, researchers at the National Institutes of Health Clinical Center (NIHCC) have developed a technology that trains a computer to read and segment certain highly variable image features.

Pages